Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?

This publication has 40 references indexed in Scilit:

• ABC of breast diseases: Breast cancer---epidemiology, risk factors, and genetics
  BMJ, 2000
• Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90)
  European Journal Of Cancer, 1997
• Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors
  JNCI Journal of the National Cancer Institute, 1996
• A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer
  Annals of Oncology, 1996
• Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials
  Cancer, 1996
• A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *
  European Journal Of Cancer, 1996
• The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients
  European Journal Of Cancer, 1992
• POTENCY AND SELECTIVITY OF THE NON-STEROIDAL AROMATASE INHIBITOR CGS 16949A IN POSTMENOPAUSAL BREAST CANCER PATIENTS
  Clinical Endocrinology, 1990
• Medical Adrenalectomy with Aminoglutethimide
  Annals of Surgery, 1978
• ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1
  The Lancet, 1896